MA01.03 The Role of Gut Microbiome in the Efficacy of Chemotherapy in Patients With Locally Advanced and Advanced Lung Cancer

Accumulating evidences have disclosed the important role of gut microbiome in modulating response immunotherapy patients with lung cancer. However, research exploring relationship intestinal flora and chemotherapy is still limited. The study to investigate correlation between efficacy locally advanced We analyzed baseline stool samples from cancer before treatment, through metagenomics microbiota. composition, diversity, function metabolic pathway microbial communities were compared among different response. From September 1, 2018 30, 2019, 64 consecutive treated included into this study. All provided samples. 33 responded treatment (responders) another 31 didn’t (non-responders). median progression-free survival was 7 months (range, 1.5-14.5). Streptococcus_mutans (P=0.026) Enterococcus_casseliflavus (P=0.049) enriched responders, while 11 bacteria including Leuconostoc_lactis (P=0.002) non-responders. Functional analysis pathways revealed that L-glutamate degradation VIII responders (P=0.014), 3 C4 photosynthetic carbon assimilation cycle non-responders (P<0.05). Patients 5 bacterial species, such as Turicibacter_sanguinis (P=0.008) had longer than those Streptococcus_anginosus (P=0.013) (HR, 0.189; 95% CI, 0.092-0.387; P< 0.0001). Purine nucleobases I other 4 In addition, significant associations certain species clinical parameters pathological pattern observed by spearman analysis. indicated specific may be associated outcome chemotherapy, which need validated prospective large studies.